The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Germline variants in urothelial carcinoma: Analysis of pathogenic and likely pathogenic variants in 645 subjects.
 
Sarah Abou Alaiwi
No Relationships to Disclose
 
Amin Nassar
No Relationships to Disclose
 
Kent William Mouw
Consulting or Advisory Role - EMD Serono; Pfizer
Research Funding - Pfizer
 
David J. Kwiatkowski
Consulting or Advisory Role - Genentech/Roche; Novartis
Research Funding - AADi; Genentech/Roche; Revolution Medicines
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - Dana Farber Cancer Hospital; Kidney Cancer Association; NCCN
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Catherine Curran
No Relationships to Disclose
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - Genome Medical; Microsoft; Syapse; Tango Therapeutics
Consulting or Advisory Role - Dynamo Therapeutics; Forest Laboratories/Actavis; Genome Medical; Illumina; InVitae; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Edward D. Esplin
Employment - Invitae
Stock and Other Ownership Interests - Invitae
 
Shan Yang
Employment - Invitae
Stock and Other Ownership Interests - Invitae
Travel, Accommodations, Expenses - Invitae
 
Judy Ellen Garber
Consulting or Advisory Role - GTx (I); Helix BioPharma; Novartis (I); ORIC Pharmaceuticals (I); pfizer (I); SV Life Sciences (I)
Research Funding - Ambry Genetics; Novartis (I)
Other Relationship - AACR; Adrienne Helis Malvin Medical Research Foundation (I); Breast Cancer Research Foundation; Diana Helis Henry Medical Foundation (I); Global Biological Standards Institute (I); James P. Wilmot Foundation (I); Susan G. Komen for the Cure (I)
 
Huma Q. Rana
No Relationships to Disclose
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb